FSSAI files three cases against Nestlé India over infant-food claims and labelling
India’s food regulator has initiated three adjudication cases involving promotional claims for NAN Excella Pro and Lactogen Pro, plus an alleged biotin non-conformance in a follow-up formula. Nestlé India says its products and labels are fully compliant with applicable regulations.
What happened
FSSAI has filed three adjudication cases against Nestle India over promotional claims on NAN Excella Pro and Lactogen Pro infant foods and a follow-up formula’s
Key facts
- Three separate adjudication cases
- Regulation 4(2) of the Food Safety and Standards (Foods for Infant Nutrition) Regulations, 2020
- Section 3 of the Infant Milk Substitutes Act, 1992
- Nestle India shares fell 1.4% to ₹1,353.10
- 2015
What changed
FSSAI has filed three adjudication cases against Nestle India over promotional claims on NAN Excella Pro and Lactogen Pro infant foods and a follow-up formula’s biotin non-conformance. Nestle says its products and labels are fully compliant and FSSAI-approved.
Why this matters
Nestlé India should urgently audit infant-nutrition claims, labels and substantiation across NAN Excella Pro and Lactogen Pro while preparing a coordinated regulatory-response plan.
What to watch
- FSSAI adjudication notices, hearing dates, interim directions or monetary penalties.
- Any order requiring withdrawal, sales suspension, relabelling or corrective advertising for the named products.
- Publication of laboratory findings, batch details or biotin variance levels.
- Nestlé India disclosures on contingent liabilities, product sales impact or changes to infant-nutrition marketing.
- Consumer complaints, pediatrician/healthcare-community reaction and social-media attention.